MedicalDataFiles.Com

P.O. Box 510949  Milwaukee, WI 53203    800 669-3337    414 272-6666 Fax 

Record Layout / Sample Data

File Description / Details:

Description: HCPCS Level II Codes Standard & Professional 
File Name: HCPCS Level II

Record Layout:
Field Type Size  Description
Code Char 5 HCPCS Code or Modifier
Short_Description Char 31 HCPCS Long Description (upper case)
Long_Description Char 254 HCPCS Long Description (upper and lower case)
Crossref Char 30 HCPCS or CPT Crossreference
Status Char 1 C-Change   N-New   D-Delete  R-Reactivate S-Change in Short Description
*Coverage Char 1

D = Special coverage instructions apply  I = Not payable by Medicare M = Non-covered by Medicare S = Non-covered by Medicare statute C = Carrier judgment

*Term_Date Char 10 Date of Code Termination
*ASC_Indic Char 2 See Explanation Below. ASC Payment Indicators: A2, D5, F4, G2, H2, H8, J7, J8, K2, K7, L1, L6, N1, P2, P3, R2, Z2, Z3
*ASC_Approved Char 2 The 'YY' indicator represents that this procedure is approved to be performed in an ambulatory surgical center.
*Gender Char 1 Sex: M-Male F-Female
*HCPCS_Pricing_Indicator Char 20 See Explanation Below. HCPCS_Pricing_Indicator: 00, 11, 12, 13, 21, 22, 31, 32, 33, 34, 35, 36, 37, 38, 39, 45, 46, 51, 52, 53, 54, 55, 56, 57, 99
*HCPCS_Multiple_Pricing_Indicator Char 20 See Explanation Below. HCPCS_Multiple_Pricing_Indicator:9,A,B,C,D,E,F
*Notes Char 254 MDF Value Added Notes

* Available in Professional Version Only

Note:  D Codes (ADA CDT dental codes) are not included in this database.  See CDT  for more information.

 
CODE SHORT_DESC LONG_DESC CROSSREF COVERAGE ASC_GRP STATUS TERM_DATE ASC_INDIC ASC_APPROV Gender MPI HCPCS_Pricing_Indicator HCPCS_Multiple_Pricing_Indicator Notes
AM PHYSICIAN, TEAM MEMBER SVC Physician, team member service QM D









AP NO DTMN OF REFRACTIVE STATE Determination of refractive state was not performed in the course of diagnostic ophthalmological examination
C









AQ PHYSICIAN SERVICE HPSA AREA Physician providing a service in an unlisted health professional shortage area (HPSA)
C









AR PHYSICIAN SCARCITY AREA Physician provider services in a physician scarcity area
C









AS ASSISTANT AT SURGERY SERVICE Physician assistant, nurse practitioner, or clinical nurse specialist services for assistant at surgery
C









AT ACUTE TREATMENT Acute treatment (this modifier should be used when reporting service 98940, 98941, 98942)
C









AU URO, OSTOMY OR TRACH ITEM Item furnished in conjunction with a urological, ostomy, or tracheostomy supply
C









JC SKIN SUBSTITUTE GRAFT Skin substitute used as a graft
C
A







JD SKIN SUB NOT USED AS A GRAFT Skin substitute not used as a graft
C
A







A4570 SPLINT Splint
I





A 52 A See also Q4049 and Q4051 for additional splint supplies.
A4580 CAST SUPPLIES (PLASTER) Cast supplies (e.g. plaster)
I





9 00 9 See also Q4001-Q4048 and Q4050 for additional cast supplies.
A4641 RADIOPHARM DX AGENT NOC Radiopharmaceutical, diagnostic, not otherwise classified
C


N1

A 51 A Note: Code A4641 should be used for Medicare billing. See CPT 78990 for commercial billing.
A4642 IN111 SATUMOMAB Indium in-111 satumomab pendetide, diagnostic, per study dose, up to 6 millicuries
C


N1

A 51 A
A4643 HIGH DOSE CONTRAST MRI Supply of additional high dose contrast material(s) during magnetic resonance imaging, e.g., gadoteridol injection
I
D 20051231


9 00 9
A4644 CONTRAST 100-199 MGS IODINE Supply of low osmolar contrast material (100-199 mgs of iodine)
I
D 20051231


9 00 9 Note: Low osmolar contrast material should be coded, when supplied, with all radiology services indicating "with contrast".
A4645 CONTRAST 200-299 MGS IODINE Supply of low osmolar contrast material (200-299 mgs of iodine)
I
D 20051231


9 00 9
A4646 CONTRAST 300-399 MGS IODINE Supply of low osmolar contrast material (300-399 mgs of iodine)
I
D 20051231


9 00 9
A4647 SUPP- PARAMAGNETIC CONTR MAT Supply of paramagnetic contrast material, eg., gadolinium
I
D 20051231


9 00 9
A4648 IMPLANTABLE TISSUE MARKER Tissue marker, implantable, any type, each
C


N1

A 57 A
A4649 SURGICAL SUPPLIES Surgical supply; miscellaneous
C





A 46 A Use of this code will result in an inquiry letter from the insurance carrier. Use a more specific code from the HCPCS book to describe the supply.
A4649 SURGICAL SUPPLIES Surgical supply; miscellaneous
C





A 46 A Use of this code will result in an inquiry letter from the insurance carrier. Use a more specific code from the HCPCS book to describe the supply.
A4650 IMPLANT RADIATION DOSIMETER Implantable radiation dosimeter, each
C


N1

A 57 A
A4651 CALIBRATED MICROCAP TUBE Calibrated microcapillary tube, each
D





A 52 A
A9150 MISC/EXPER NON-PRESCRIPT DRU Non-prescription drugs
D





A 57 A Note: The following codes do not imply that codes in other sections are necessarily covered
C8904 MRI W/O CONT, BREAST, UNI Magnetic resonance imaging without contrast, breast; unilateral
D YY

Z2 YY
A 53 A
C8910 MRA W/O CONT, CHEST Magnetic resonance angiography without contrast, chest (excluding myocardium)
D YY

Z2 YY
A 53 A
C8911 MRA W/O FOL W/CONT, CHEST Magnetic resonance angiography without contrast followed by with contrast, chest (excluding myocardium)
D YY

Z2 YY
A 53 A
C8912 MRA W/CONT, LWR EXT Magnetic resonance angiography with contrast, lower extremity
D YY

Z2 YY
A 53 A
C8913 MRA W/O CONT, LWR EXT Magnetic resonance angiography without contrast, lower extremity
D YY

Z2 YY
A 53 A
C8914 MRA W/O FOL W/CONT, LWR EXT Magnetic resonance angiography without contrast followed by with contrast, lower extremity
D YY

Z2 YY
A 53 A
C8918 MRA W/CONT, PELVIS Magnetic resonance angiography with contrast, pelvis
D YY

Z2 YY
A 53 A
C9236 INJECTION, ECULIZUMAB Injection, eculizumab, 10 mg J1300 D
D 20071231


A 53 A
C9237 INJ, LANREOTIDE ACETATE Injection, lanreotide acetate, 1 mg J1930 D
D 20081231 K2

A 53 A
E0325 URINAL MALE JUG-TYPE Urinal; male, jug-type, any material
D




M A 32 A
G0103 PSA SCREENING Prostate cancer screening; prostate specific antigen test (psa)
D




M A 21 A
G0130 SINGLE ENERGY X-RAY STUDY Single energy x-ray absorptiometry (sexa) bone density study, one or more sites; appendicular skeleton (peripheral) (eg, radius, wrist, heel)
D YY

Z3 YY
A 11 A
G0254 PET IMAGE BRST EVAL TO TX PET imaging for breast cancer, full and partial- ring PET scanners only, evaluation of response to treatment, performed during course of treatment
C
D 20050331

F A 11 A
G0369 PHARM FEE 1ST MONTH TRANSPLA Pharmacy supply fee for initial immunosuppressive drug(s) first month following transplant Q0510 D
D 20051231


A 46 A
G0370 PHARMACY FEE ORAL CANCER ETC Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s) Q0511 Q0512 D
D 20051231


A 46 A
G0371 PHARM DISPENSE INHALATION 30 Pharmacy dispensing fee for inhalation drug(s); per 30 days Q0513 D
D 20051231


A 46 A
G0374 PHARM DISPENSE INHALATION 90 Pharmacy dispensing fee for inhalation drug(s); per 90 days Q0514 D
D 20051231


A 46 A
G0416 SAT BIOPSY PROSTATE 1-20 SPC Surgical pathology, gross and microscopic examination for prostate needle saturation biopsy sampling, 1-20 specimens
C
A


M A 13 A
G0417 SAT BIOPSY PROSTATE 21-40 Surgical pathology, gross and microscopic examination for prostate needle saturation biopsy sampling, 21-40 specimens
C
A


M A 13 A
G0418 SAT BIOPSY PROSTATE 41-60 Surgical pathology, gross and microscopic examination for prostate needle saturation biopsy sampling, 41-60 specimens
C
A


M A 13 A
G0419 SAT BIOPSY PROSTATE: >60 Surgical pathology, gross and microscopic examination for prostate needle saturation biopsy sampling, greater than 60 specimens
C
A


M A 13 A
G8464 PT INELIG; LO TO NO DTER RSK Clinician documented that prostate cancer patient is not an eligible candidate for adjuvant hormonal therapy; low or intermediate risk of recurrence or risk of recurrence not determined
C




M 9 00 9
G8465 HIGH RISK RECURRENCE PRO CA High risk of recurrence of prostate cancer
C




M 9 00 9
G9077 ONC DX PROSTATE T1NO PROGRES Oncology; disease status; prostate cancer, limited to adenocarcinoma as predominant cell type; t1-t2c and gleason 2-7 and psa < or equal to 20 at diagnosis with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
C




M 9 00 9
G9079 ONC DX PROSTATE T3B-T4NOPROG Oncology; disease status; prostate cancer, limited to adenocarcinoma as predominant cell type; t3b-t4, any n; any t, n1 at diagnosis with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
C




M 9 00 9
G9113 ONC DX OVARIAN STG1A-B NO PR Oncology; disease status; ovarian cancer, limited to epithelial cancer; pathologic stage IA-B (grade 1) without evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
C




F 9 00 9
G9115 ONC DX OVARIAN STG3/4 NOPROG Oncology; disease status; ovarian cancer, limited to epithelial cancer; pathologic stage iii-iv; without evidence of progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
C




F 9 00 9
G9116 ONC DX OVARIAN RECURRENCE Oncology; disease status; ovarian cancer, limited to epithelial cancer; evidence of disease progression, or recurrence, and/or platinum resistance (for use in a medicare-approved demonstration project)
C




F 9 00 9
H1000 PRENATAL CARE ATRISK ASSESSM Prenatal care, at-risk assessment
I




F 9 00 9
H1001 ANTEPARTUM MANAGEMENT Prenatal care, at-risk enhanced service; antepartum management
I




F 9 00 9
J0395 ARBUTAMINE HCL INJECTION Injection, arbutamine HCl, 1 mg
D
S
N1

A 51 A
J0694 CEFOXITIN SODIUM INJECTION Injection, cefoxitin sodium, 1 gm Q0090 D


N1

A 51 A
J1562 VIVAGLOBIN, INJ Injection, immune globulin (vivaglobin), 100 mg
C YY

K2 YY
A 51 A Use J1562 for Gammar-IV, Sandoglobulin, Panglobulin, and Polygam SD
J1750 INJ IRON DEXTRAN Injection, iron dextran, 50 mg
D YY R

YY
A 51 A
J2355 OPRELVEKIN INJECTION Injection, oprelvekin, 5 mg
D YY

K2 YY
A 51 A
J2357 OMALIZUMAB INJECTION Injection, omalizumab, 5 mg
C YY

K2 YY
A 51 A
J2405 ONDANSETRON HCL INJECTION Injection, ondansetron hydrochloride, per 1 mg
D YY

K2 YY
A 51 A Note: Payment by Medicare is restricted to the following ICD-9-CM codes: V58.1 plus the diagnostic condition.
J2425 PALIFERMIN INJECTION Injection, palifermin, 50 micrograms
C YY

K2 YY
A 51 A
J2430 PAMIDRONATE DISODIUM /30 MG Injection, pamidronate disodium, per 30 mg
D YY

K2 YY
A 51 A
J2469 PALONOSETRON HCL Injection, palonosetron HCl, 25 mcg
C YY S
K2 YY
A 51 A
J2504 PEGADEMASE BOVINE, 25 IU Injection, pegademase bovine, 25 IU
D YY

K2 YY
A 51 A
J3365 UROKINASE 250,000 IU INJ Injection, IV, urokinase, 250,000 i.u. vial Q0089 D YY

K2 YY
A 51 A
J7611 ALBUTEROL NON-COMP CON Albuterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME, concentrated form, 1 mg
I
R



9 00 9
J7612 LEVALBUTEROL NON-COMP CON Levalbuterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME, concentrated form, 0.5 mg
I
R



9 00 9
J7613 ALBUTEROL NON-COMP UNIT Albuterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose, 1 mg
I
R



9 00 9
J7614 LEVALBUTEROL NON-COMP UNIT Levalbuterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose, 0.5 mg
I
R



9 00 9
J9000 DOXORUBICIN HCL INJECTION Injection, doxorubicin hydrochloride, 10 mg
D
C
N1

A 51 A The cost of the chemotherapy drug only, not to include the administration. See also J8999.
L3215 ORTHOPEDIC FTWEAR LADIES OXF Orthopedic footwear, ladies shoe, oxford, each
S




F 9 00 9
L3216 ORTHOPED LADIES SHOES DPTH I Orthopedic footwear, ladies shoe, depth inlay, each
S




F 9 00 9
L3217 LADIES SHOES HIGHTOP DEPTH I Orthopedic footwear, ladies shoe, hightop, depth inlay, each
S




F 9 00 9
L3650 SHLDER FIG 8 ABDUCT RESTRAIN Shoulder orthosis, figure of eight design abduction restrainer, prefabricated, includes fitting and adjustment
C





A 38 A Note: The procedures in this section are considered as 'base' or 'basic procedures,' and may be modified by listing procedures from the 'additions section,' and adding them to the base procedure.
L3940 DORSAL WRIST W/ OUTRIGGER AT Wrist hand finger orthosis, dorsal wrist, with outrigger attachment, prefabricated, includes fitting and adjustment L3931 C
D 20071231


A 38 A
L3948 FINGER KNUCKLE BENDER Finger orthosis, finger knuckle bender, prefabricated, includes fitting and adjustment L3925 C
D 20071231


A 38 A
L3950 OPPENHEIMER W/ KNUCKLE BEND Wrist hand finger orthosis, combination oppenheimer, with knuckle bender and two attachments, prefabricated, includes fitting and adjustment L3931 C
D 20071231


A 38 A
L3952 OPPENHEIMER W/ REV KNUCKLE 2 Wrist hand finger orthosis, combination oppenheimer, with reverse knuckle and two attachments, prefabricated, includes fitting and adjustment L3931 C
D 20071231


A 38 A
L6000 PAR HAND ROBIN-AIDS THUM REM Partial hand, robin-aids, thumb remaining (or equal)
C





A 38 A Note: The procedures in L6000-L6599 are considered as base or basic procedures and may be modified by listing procedures from the "additions" sections. The base procedures include only standard friction wrist and control cable system unless otherwise sp
L6600 POLYCENTRIC HINGE PAIR Upper extremity additions, polycentric hinge, pair
C





A 38 A Note: The following procedures/modifications/components may be added to other base procedures. The items in this section should reflect the additional complexity of each modification procedure, in addition to base procedure, at the time of the original
Q0179 ONDANSETRON HCL 8 MG ORAL Ondansetron hydrochloride 8 mg, oral, FDA approved prescription anti-emetic, for use as a complete therapeutic substitute for an IV anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
D YY S
K2 YY
A 51 A
S2401 FETAL SURG URIN TRAC OBSTR Repair, urinary tract obstruction in the fetus, procedure performed in utero
I




F 9 00 9
S9001 HOME UTERINE MONITOR WITH OR Home uterine monitor with or without associated nursing services
I




F 9 00 9

HCPCS_Multiple_Pricing_Indicator

9 = Not applicable as HCPCS not priced separately by part B (pricing indicator is 00) or value is not established (pricing indicator is '99') Noncovered by Medicare

 A = Not applicable as HCPCS priced under one methodology Carrier Discretion

 B = Professional component of HCPCS priced using RVU's, while technical component and global service priced by Medicare part B carriers

 C = Physician interpretation of clinical lab service is priced under physician fee schedule using RVU's, while pricing of lab service is paid under clinical lab fee schedule

 D = Service performed by physician is priced under physician fee schedule using RVU's, while service performed by clinical psychologist is priced under clinical psychologist fee schedule (not applicable as of January 1, 1998)

 E = Service performed by physician is priced under physician fee schedule using RVU's, service performed by clinical psychologist is priced under clinical psychologist's fee schedule and service performed by clinical social worker is priced under clinical social worker fee schedule (not applicable as of January 1, 1998)

 F = Service performed by physician is priced under physician fee schedule by carriers, service performed by clinical psychologist is priced under clinical psychologist's fee schedule and service performed by clinical social worker is priced under clinical social worker fee schedule (not applicable as of January 1, 1998)

 G = Clinical lab service priced under reasonable charge when service is submitted on claim with blood products, while service is priced under clinical lab fee schedule when there are no blood products on claim.

HCPCS_Pricing_Indicator

00, 11, 12, 13, 21, 22, 31, 32, 33, 34, 35, 36, 37, 38, 39, 45, 46, 51, 52, 53, 54, 55, 56, 57, 99

00 = Service not separately priced by Part B (e.g., services not covered, bundled, used by part a only, etc.) Physician Fee Schedule And Non-Physician Practitioners Linked To The Physician Fee Schedule

11 = Price established using national rvu's

12 = Price established using national anesthesia base units

13 = Price established by carriers (e.g., not otherwise classified, individual determination, carrier discretion) Clinical Lab Fee Schedule

21 = Price subject to national limitation amount

22 = Price established by carriers (e.g., gap-fills, carrier established panels) Durable Medical Equipment, Prosthetics, Orthotics, Supplies And Surgical Dressings

31 = Frequently serviced DME (price subject to floors and ceilings)

32 = Inexpensive & routinely purchased DME (price subject to floors and ceilings)

33 = Oxygen and oxygen equipment (price subject to floors and ceilings)

34 = DME supplies (price subject to floors and ceilings)

35 = Surgical dressings (price subject to floors and ceilings)

36 = Capped rental DME (price subject to floors and ceilings)

37 = Ostomy, tracheostomy and urological supplies (price subject to floors and ceilings)

38 = Orthotics, prosthetics, prosthetic devices & vision services (price subject to floors and ceilings)

39 = Parenteral and Enteral Nutrition

45 = Customized DME items

46 = Carrier priced (e.g., not otherwise classified, individual determination, carrier discretion, gap-filled amounts)

51 = Drugs

52 = Reasonable charge

53 = Statute

54 = Vaccinations

55 = Priced by carriers under clinical psychologist fee schedule (not applicable as of January 1, 1998)

56 = Priced by carriers under clinical social worker fee schedule (not applicable as of January 1, 1998)

57 = Other carrier priced

99 = Value not established

ASC Payment Indicator Definition

A2, D5, F4, G2, H2, H8, J7, J8, K2, K7, L1, L6, N1, P2, P3, R2, Z2, Z3

Indicator Payment Indicator Definition
A2 Surgical procedure on ASC list in CY 2007; payment based on OPPS relative payment weight.
D5 Deleted/discontinued code; no payment made.
F4 Corneal tissue acquisition, hepatitis B vaccine; paid at reasonable cost
G2 Non office-based surgical procedure added in CY 2008 or later; payment based on OPPS relative payment weight.
H2 Brachytherapy source paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate.
H8 Device-intensive procedure on ASC list in CY 2007; paid at adjusted rate.
J7 OPPS pass-through device paid separately when provided integral to a surgical procedure on ASC list; payment contractor-priced.
J8 Device-intensive procedure added to ASC list in CY 2008 or later; paid at adjusted rate.
K2 Drugs and biologicals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate.
K7 Unclassified drugs and biologicals; payment contractor-priced.
L1 Influenza vaccine; pneumococcal vaccine.   Packaged item/service; no separate payment made.  
L6 New Technology Intraocular Lens (NTIOL); special payment.
N1 Packaged service/item; no separate payment made.
P2 Office-based surgical procedure added to ASC list in CY 2008 or later with MPFS nonfacility PE RVUs; payment based on OPPS relative payment weight.
P3 Office-based surgical procedure added to ASC list in CY 2008 or later with MPFS nonfacility PE RVUs; payment based on MPFS nonfacility PE RVUs.
R2 Office-based surgical procedure added to ASC list in CY 2008 or later without MPFS nonfacility PE RVUs; payment based on OPPS relative payment weight.
Z2 Radiology service paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS relative payment weight.
Z3 Radiology service paid separately when provided integral to a surgical procedure on ASC list; payment based on MPFS nonfacility PE RVUs.